Canaccord Genuity analyst William Plovanic has maintained their bullish stance on STIM stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
William Plovanic has given his Buy rating due to a combination of factors tied to Neuronetics’ path to scale and improving cash dynamics. He views the combination of Neuronetics and Greenbrook as strategically sound, arguing that the larger, integrated platform has already demonstrated improved financial health, including achieving positive operating cash flow in Q4 2025, something each business struggled to reach on a stand-alone basis.
Plovanic also cites the reaffirmed 2026 outlook as a key support for his thesis, with management guiding to solid revenue growth, improving margins, and a narrowing cash burn alongside newly announced cost reductions that should yield meaningful savings from mid-2026. While acknowledging governance noise from an activist investor and the upcoming CFO change, he interprets these as manageable events within a broader, still-intact turnaround story rather than fundamental cracks in the business, reinforcing his Buy recommendation.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $3.00 price target.
STIM’s price has also changed moderately for the past six months – from $2.830 to $1.760, which is a -37.81% drop .